News

ESFRI Open Session on response to COVID-19 pandemic

29. 03. 2021 News PR

The 75th ESFRI Forum Plenary was held virtually on 23rd – 24th March 2021. The first Open Session organised as a part of the ESFRI meeting brought together the ESFRI Delegates and representatives of the ESFRI Research Infrastructures to discuss the response to the COVID-19 pandemic. The main focus was put on the activities of…

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

25. 03. 2021 News Paper Publication

Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its…

CCP celebrates the Rare Disease Day 2021

26. 02. 2021 News PR

The CCP primary goal is to perform excellent research. In the period 2021 – 2030, together with other foreign centers gathered in the International Mouse Phenotyping Consortium we plan  to deliver jointly broad-based genomic insights into the function of human genetic variation in both coding and non-coding sequences that underpin future developments in precision medicine,…

We lit the Dancing House blue, hoping for a cure for little Oliver and the other “angel children”, on 15th February

17. 02. 2021 News PR

Dancing house blue. It shone in honor of all the “angelic families” who face a difficult fate every day. On 15th February, we celebrated International Angelman Syndrome Day. More than 100 patients live with this rare genetic disease among us in the Czech Republic. The initiators of the event are the parents of little Oliver…

EuroPDX and PDXNet consortia publish a milestone paper on PDX reliability

12. 02. 2021 Information News Service

Woo, X.Y., Giordano, J., Srivastava, A. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53, 86–99 (2021). https://doi.org/10.1038/s41588-020-00750-6 Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting…

IMPC 2020 annual highlights

Do not miss the best of IMPC work, including research publications, data updates, global collaborations in 2020, and IMPC plans for the future. https://review.mousephenotype.org/

IMPC elects a new senior leadership team

02. 02. 2021 Information News

The IMPC is pleased to announce the election of a new Senior Leadership Team. Radislav Sedláček is the new Chair of the IMPC, and Yann Herault the new Vice-Chair. Steve Brown, who was the Chair of the IMPC, has stepped down to become the Past Chair. Read the full article at the IMPC website.

Join a press conference on a new antibody against covid-19 with Radislav Sedlacek and Daniel Ruzek today

26. 01. 2021 News PR

Czech scientists tested a new antibody against covid-19, which is suitable for prevention and treatment and prevents the virus from mutating. Radislav Sedlacek from CCP and Daniel Ruzicka from the Biology Centre of the Czech Academy of Sciences and the Veterinary Research Institute will answer questions of journalists today (26th January) at 15:00 during a…

Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease

25. 01. 2021 News Paper Publication

Researchers from the Czech Centre for Phenogenomics contributed to the paper “Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease“ Raoul De Gasparo, Mattia Pedotti, Luca Simonelli, Petr Nickl, Frauke Muecksch, Julio C. C. Lorenzi, Federica Mazzola, Davide Magrì, Tereza Michalcikova, Jan Haviernik, Vaclav Honig, Irene Cassaniti, Elena Percivalle, Blanka Mrazkova, Natalie Polakova, Andrea…

Infrafrontier trans-national access call: COVID-19 therapeutics pipeline

19. 01. 2021 Call

Application deadline: EXTENDED 28 Febuary 2021 Application costs: This TA Call is free-of-charge for the selected applicants. Main objective of this INFRAFRONTIER2020 Trans-national Access Call is to provide extensive user support to the selected projects for assessing novel potential vaccine and treatment compounds for COVID-19. As starting material for the TA service, only sufficient amounts of…

1 2 3 9